

Therapeutic Alternatives Prior Authorization with Quantity Limit Program Summary

POLICY REVIEW CYCLE

Effective Date
05-05-2025

Date of Origin

OBJECTIVE

The intent of the Therapeutic Alternatives Prior Authorization with Quantity Limit is to promote the use of lower cost, clinically appropriate, formulary alternatives over the high cost targets. Targets will be approved when the patient has experienced an inadequate response to optimized therapy of the lower cost alternative(s); the patient has a documented intolerance, FDA labeled contraindication, or hypersensitivity to the lower cost alternatives that is not expected to occur with the requested agent; or the prescriber has provided documentation and the pharmacist has reviewed and approved the patient's needs for the requested agent over the lower cost alternative(s).

POLICY AGENT SUMMARY PRIOR AUTHORIZATION

Target Brand Agent(s)	Target Generic Agent(s)	Strength	Targeted MSC	Available MSC	Final Age Limit	Preferred Status
Kitabis pak ; Tobi ; Tobramycin		300 MG/5ML	M ; N ; O	M ; O ; Y		
Bethkis		300 MG/4ML	M ; N ; O	O ; Y		
Librax		5-2.5 MG	M ; N ; O	O ; Y		
Ativan		0.5 MG ; 1 MG ; 2 MG	M ; N ; O	O ; Y		
Wellbutrin xl		150 MG	M ; N ; O	O ; Y		
Wellbutrin xl		300 MG	M ; N ; O	O ; Y		
Flurazepam hydrochloride		15 MG	M ; N ; O	N		
Flurazepam hydrochloride		30 MG	M ; N ; O	N		
Absorica		10 MG ; 20 MG ; 25 MG ; 30 MG ; 35 MG ; 40 MG	M ; N ; O	O ; Y		
Absorica Id		16 MG ; 24 MG ; 32 MG ; 8 MG	M ; N ; O	N		
Sitavig	Acyclovir Buccal Tab 50 MG	50 MG	M ; N ; O ; Y	N		
Zovirax	Acyclovir Cream 5%	5 %	M ; N ; O ; Y	O ; Y		
Xerese	Acyclovir-Hydrocortisone Cream 5-1%	5-1 %	M ; N ; O ; Y	N		
Adapalene	Adapalene Pads 0.1%	0.1 %	M ; N ; O ; Y	N		
Cabtreo	adapalene-benzoyl peroxide-clindamycin gel	0.15-3.1-1.2 %	M ; N ; O ; Y	N		
Azelex	Azelaic Acid Cream 20%	20 %	M ; N ; O ; Y	N		
Alphagan p	Brimonidine Tartrate Ophth Soln 0.15%	0.15 %	M ; N ; O ; Y	O ; Y		
Aplenzin	bupropion hbr tab er	174 MG ; 348 MG ; 522 MG	M ; N ; O ; Y	N		
	Butalbital-Acetaminophen Tab 50-300 MG	50-300 MG	M ; N ; O ; Y	Y		
Calcipotriene ; Sorilux	Calcipotriene Foam 0.005%	0.005 %	M ; N ; O ; Y	M ; N		
Chlorzoxazone	Chlorzoxazone Tab 250 MG	250 MG	M ; N ; O ; Y	M ; Y		

Target Brand Agent(s)	Target Generic Agent(s)	Strength	Targeted MSC	Available MSC	Final Age Limit	Preferred Status
	Chlorzoxazone Tab 375 MG	375 MG	M ; N ; O ; Y	Y		
	Chlorzoxazone Tab 750 MG	750 MG	M ; N ; O ; Y	Y		
Amrix	cyclobenzaprine hcl cap er	15 MG ; 30 MG	M ; N ; O ; Y	O ; Y		
	Cyclobenzaprine HCl Tab 7.5 MG	7.5 MG	M ; N ; O ; Y	Y		
Zipsor	Diclofenac Potassium Cap 25 MG	25 MG	M ; N ; O ; Y	O ; Y		
Cambia	Diclofenac Potassium Packet 50 MG	50 MG	M ; N ; O ; Y	O ; Y		
	Diclofenac Potassium Tab	25 MG	M ; N ; O ; Y	Y		
Diflorasone diacetate	Diflorasone Diacetate Cream 0.05%	0.05 %	M ; N ; O ; Y	M		
	Diflorasone Diacetate Oint 0.05%	0.05 %	M ; N ; O ; Y	Y		
Phospholine iodide	Echothiophate Iodide Ophth For Soln 0.125%	0.125 %	M ; N ; O ; Y	N		
Ecoza	Econazole Nitrate Foam 1%	1 %	M ; N ; O ; Y	N		
Neffy	epinephrine nasal spray	1 MG/0.1ML	M ; N ; O ; Y	N		
Neffy	epinephrine nasal spray	2 MG/0.1ML	M ; N ; O ; Y	N		
Ergomar	Ergotamine Tartrate SL Tab 2 MG	2 MG	M ; N ; O ; Y	N		
Cafergot ; Ergotamine tartrate/caffe	Ergotamine w/ Caffeine Tab 1-100 MG	1-100 MG	M ; N ; O ; Y	N ; O ; Y		
Fenoglide	Fenofibrate Tab 120 MG	120 MG	M ; N ; O ; Y	O ; Y		
Fenoprofen calcium ; Fenopron ; Nalfon	fenoprofen calcium cap	200 MG ; 300 MG ; 400 MG	M ; N ; O ; Y	M ; N ; O ; Y		
Fenoprofen calcium ; Nalfon	Fenoprofen Calcium Tab 600 MG	600 MG	M ; N ; O ; Y	N ; Y		
Flurandrenolide	Flurandrenolide Lotion 0.05%	0.05 %	M ; N ; O ; Y	N ; Y		
Halcinonide ; Halog	Halcinonide Soln 0.1%	0.1 %	M ; N ; O ; Y	N		
Lexette	Halobetasol Propionate Foam 0.05%	0.05 %	M ; N ; O ; Y	O ; Y		
Ala-scalp ; Hydrocortisone	Hydrocortisone Lotion 2%	2 %	M ; N ; O ; Y	M		
	Ketoconazole Foam 2%	2 %	M ; N ; O ; Y	Y		
Ketoprofen ; Kiprofen	Ketoprofen Cap 25 MG	25 MG	M ; N ; O ; Y	M		
Ketoprofen	Ketoprofen Cap 50 MG	50 MG	M ; N ; O ; Y	N		
Ketoprofen er	Ketoprofen Cap ER 24HR 200 MG	200 MG	M ; N ; O ; Y	N		
Luliconazole ; Luzu	Luliconazole Cream 1%	1 %	M ; N ; O ; Y	M		
	Mefenamic Acid Cap 250 MG	250 MG	M ; N ; O ; Y	Y		
	meloxicam cap	10 MG ; 5 MG	M ; N ; O ; Y	Y		
Methocarbamol	Methocarbamol Tab	1000 MG	M ; N ; O ; Y	N ; Y		
Noritrate	Metronidazole Cream 1%	1 %	M ; N ; O ; Y	N		
	Mupirocin Calcium Cream 2%	2 %	M ; N ; O ; Y	Y		
Naftifine hydrochloride	Naftifine HCl Cream 1%	1 %	M ; N ; O ; Y	N		
	Naftifine HCl Cream 2%	2 %	M ; N ; O ; Y	Y		
Naftin	Naftifine HCl Gel 1%	1 %	M ; N ; O ; Y	N		
Naftin	Naftifine HCl Gel 2%	2 %	M ; N ; O ; Y	O ; Y		
Naprelan	Naproxen Sodium Tab ER 24HR 375 MG (Base Equiv)	375 MG	M ; N ; O ; Y	O ; Y		
Naprelan	Naproxen Sodium Tab ER 24HR 500 MG (Base Equiv)	500 MG	M ; N ; O ; Y	O ; Y		

Target Brand Agent(s)	Target Generic Agent(s)	Strength	Targeted MSC	Available MSC	Final Age Limit	Preferred Status
Naprelan	Naproxen Sodium Tab ER 24HR 750 MG (Base Equiv)	750 MG	M ; N ; O ; Y	O ; Y		
Coxanto ; Oxaprozin	oxaprozin cap	300 MG	M ; N ; O ; Y	M		
Oxistat	Oxiconazole Nitrate Cream 1%	1 %	M ; N ; O ; Y	O ; Y		
Oxistat	Oxiconazole Nitrate Lotion 1%	1 %	M ; N ; O ; Y	N		
Oxycodone/acetaminophen ; Prolate	Oxycodone w/ Acetaminophen Tab 10-300 MG	10-300 MG	M ; N ; O ; Y	M		
Nalocet ; Oxycodone/acetaminophen	Oxycodone w/ Acetaminophen Tab 2.5-300 MG	2.5-300 MG	M ; N ; O ; Y	M		
Oxycodone/acetaminophen ; Prolate	Oxycodone w/ Acetaminophen Tab 5-300 MG	5-300 MG	M ; N ; O ; Y	M		
Oxycodone and acetaminoph ; Prolate	Oxycodone w/ Acetaminophen Tab 7.5-300 MG	7.5-300 MG	M ; N ; O ; Y	M		
Rhofade	oxymetazoline hcl cream	1 %	M ; N ; O ; Y	N		
Denavir	Penciclovir Cream 1%	1 %	M ; N ; O ; Y	O ; Y		
Cuprimine	penicillamine cap	250 MG	M ; N ; O ; Y	O ; Y		
	Prednisolone Sod Phosphate Oral Soln 10 MG/5ML (Base Equiv)	10 MG/5ML	M ; N ; O ; Y	Y		
	Prednisolone Tab 5 MG	5 MG	M ; N ; O ; Y	Y		
Inderal xl ; Innopran xl	Propranolol HCl Sustained-Release Beads Cap ER 24HR 120 MG	120 MG	M ; N ; O ; Y	N		
Inderal xl ; Innopran xl	Propranolol HCl Sustained-Release Beads Cap ER 24HR 80 MG	80 MG	M ; N ; O ; Y	N		
Doral ; Quazepam	Quazepam Tab 15 MG	15 MG	M ; N ; O ; Y	M ; N		
Ertaczo	Sertaconazole Nitrate Cream 2%	2 %	M ; N ; O ; Y	N		
Exelderm ; Sulconazole nitrate	Sulconazole Nitrate Cream 1%	1 %	M ; N ; O ; Y	M		
Exelderm ; Sulconazole nitrate	Sulconazole Nitrate Solution 1%	1 %	M ; N ; O ; Y	M		
Zembrace symtouch	Sumatriptan Succinate Solution Auto-injector 3 MG/0.5ML	3 MG/0.5ML	M ; N ; O ; Y	N		
Treximet	Sumatriptan-Naproxen Sodium Tab 85-500 MG	85-500 MG	M ; N ; O ; Y	O ; Y		
Tobi podhaler	tobramycin inhal cap	28 MG	M ; N ; O ; Y	N		
Kenalog ; Triamcinolone acetonide	triamcinolone acetonide aerosol soln	0.147 MG/GM	M ; N ; O ; Y	N ; O ; Y		
Reltone ; Ursodiol	Ursodiol Cap	200 MG	M ; N ; O ; Y	M		
Reltone ; Ursodiol	Ursodiol Cap	400 MG	M ; N ; O ; Y	M		
Zyflo	zileuton tab	600 MG	M ; N ; O ; Y	N		
	Zileuton Tab ER 12HR 600 MG	600 MG	M ; N ; O ; Y	Y		
Airduo respiclick 113/14	fluticasone-salmeterol aer powder ba	113-14 MCG/ACT	M ; N ; O	M		
Airduo respiclick 232/14	fluticasone-salmeterol aer powder ba	232-14 MCG/ACT	M ; N ; O	M		
Airduo respiclick 55/14	fluticasone-salmeterol aer powder ba	55-14 MCG/ACT	M ; N ; O ; Y	M		
Carbinoxamine maleate	carbinoxamine maleate tab	6 MG	M ; N ; O ; Y	M		
Epinephrine	epinephrine solution auto-injector	0.15 MG/0.15ML	M ; N ; O ; Y	N		

Target Brand Agent(s)	Target Generic Agent(s)	Strength	Targeted MSC	Available MSC	Final Age Limit	Preferred Status
Epinephrine	epinephrine solution auto-injector	0.3 MG/0.3ML	M ; N ; O ; Y	M ; N ; O ; Y		
Konvomep ; Zegerid	omeprazole-sodium bicarbonate cap ; omeprazole-sodium bicarbonate for oral susp ; omeprazole-sodium bicarbonate powd pack for susp	2-84 MG/ML ; 20-1100 MG ; 20-1680 MG ; 40-1100 MG ; 40-1680 MG	M ; N ; O ; Y	N ; O ; Y		
Sovuna	hydroxychloroquine sulfate tab	200 MG	M ; N ; O ; Y	N ; O ; Y		
Sovuna	hydroxychloroquine sulfate tab	300 MG	M ; N ; O ; Y	N ; Y		

POLICY AGENT SUMMARY QUANTITY LIMIT

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	QL Amount	Dose Form	Day Supply	Duration	Addtl QL Info	Allowed Exceptions	Targeted NDCs When Exclusions Exist
	Butalbital-Acetaminophen Tab 50-300 MG	50-300 MG	180	Tablets	30	DAYS			
	Chlorzoxazone Tab 375 MG	375 MG	120	Tablets	30	DAYS			
	Chlorzoxazone Tab 750 MG	750 MG	120	Tablets	30	DAYS			
	Cyclobenzaprine HCl Tab 7.5 MG	7.5 MG	90	Tablets	30	DAYS			
	Diclofenac Potassium Tab	25 MG	120	Tablets	30	DAYS			
	Difforason Diacetate Oint 0.05%	0.05 %	180	Grams	90	DAYS			
	Ketoconazole Foam 2%	2 %	100	Grams	30	DAYS			
	Mefenamic Acid Cap 250 MG	250 MG	120	Capsules	30	DAYS			
	Meloxicam Cap 10 MG	10 MG	30	Capsules	30	DAYS			
	Meloxicam Cap 5 MG	5 MG	30	Capsules	30	DAYS			
	Mupirocin Calcium Cream 2%	2 %	120	Grams	90	DAYS			
	Naftifine HCl Cream 2%	2 %	60	Grams	30	DAYS			
	Prednisolone Sod Phosphate Oral Soln 10 MG/5ML (Base Equiv)	10 MG/5ML	900	mLs	30	DAYS			
	Zileuton Tab ER 12HR 600 MG	600 MG	120	Tablets	30	DAYS			
Absorica	Isotretinoin Cap 10 MG	10 MG	60	Capsules	30	DAYS			
Absorica	Isotretinoin Cap 20 MG	20 MG	60	Capsules	30	DAYS			
Absorica	Isotretinoin Cap 25 MG	25 MG	60	Capsules	30	DAYS			
Absorica	Isotretinoin Cap 30 MG	30 MG	60	Capsules	30	DAYS			
Absorica	Isotretinoin Cap 35 MG	35 MG	60	Capsules	30	DAYS			

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	QL Amount	Dose Form	Day Supply	Duration	Addtl QL Info	Allowed Exceptions	Targeted NDCs When Exclusions Exist
Absorica	Isotretinoin Cap 40 MG	40 MG	60	Capsules	30	DAYS			
Absorica Id	Isotretinoin Micronized Cap 16 MG	16 MG	60	Capsules	30	DAYS			
Absorica Id	Isotretinoin Micronized Cap 24 MG	24 MG	60	Capsules	30	DAYS			
Absorica Id	Isotretinoin Micronized Cap 32 MG	32 MG	60	Capsules	30	DAYS			
Absorica Id	Isotretinoin Micronized Cap 8 MG	8 MG	60	Capsules	30	DAYS			
Adapalene	Adapalene Pads 0.1%	0.1 %	28	Swabs	28	DAYS			
Airduo respiclick 113/14 ; Fluticasone propionate/sa	Fluticasone-Salmeterol Aer Powder BA 113-14 MCG/ACT	113-14 MCG/ACT	1	Inhaler	30	DAYS			
Airduo respiclick 232/14 ; Fluticasone propionate/sa	Fluticasone-Salmeterol Aer Powder BA 232-14 MCG/ACT	232-14 MCG/ACT	1	Inhaler	30	DAYS			
Airduo respiclick 55/14 ; Fluticasone propionate/sa	Fluticasone-Salmeterol Aer Powder BA 55-14 MCG/ACT	55-14 MCG/ACT	1	Inhaler	30	DAY			
Alphagan p	Brimonidine Tartrate Ophth Soln 0.15%	0.15 %	5	mLs	20	DAYS			
Amrix	Cyclobenzaprine HCl Cap ER 24HR 15 MG	15 MG	30	Capsules	30	DAYS			
Amrix	Cyclobenzaprine HCl Cap ER 24HR 30 MG	30 MG	30	Capsules	30	DAYS			
Ativan	Lorazepam Tab 0.5 MG	0.5 MG	150	Tablets	30	DAYS			
Ativan	Lorazepam Tab 1 MG	1 MG	150	Tablets	30	DAYS			
Ativan	Lorazepam Tab 2 MG	2 MG	150	Tablets	30	DAYS			
Azelex	Azelaic Acid Cream 20%	20 %	30	Grams	30	DAYS			
Bethkis	Tobramycin Nebu Soln 300 MG/4ML	300 MG/4ML	224	mLs	56	DAYS	Any tobramycin product and Cayston cannot be filled within 28 days of each other. 224 mL = 56 ampules		
Cafergot ; Ergotamine tartrate/caffe	Ergotamine w/ Caffeine Tab 1-100 MG	1-100 MG	40	Tablets	28	DAYS			
Calcipotriene ; Sorilux	Calcipotriene Foam 0.005%	0.005 %	120	Grams	30	DAYS			
Cambia	Diclofenac Potassium Packet 50 MG	50 MG	9	Packets	30	DAYS			
Carbinoxamine maleate	carbinoxamine maleate tab	6 MG	150	Tablets	30	DAYS			690670 24020 ; 736840 11060
Chlorzoxazone	Chlorzoxazone Tab 250 MG	250 MG	120	Tablets	30	DAYS			

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	QL Amount	Dose Form	Day Supply	Duration	Addtl QL Info	Allowed Exceptions	Targeted NDCs When Exclusions Exist
Coxanto ; Oxaprozin	oxaprozin cap	300 MG	120	Capsules	30	DAYS			
Cuprimine	Penicillamine Cap 250 MG	250 MG	480	Capsules	30	DAYS			
Diflorasone diacetate	Diflorasone Diacetate Cream 0.05%	0.05 %	180	Grams	90	DAYS			
Doral ; Quazepam	Quazepam Tab 15 MG	15 MG	30	Tablets	30	DAYS			
Ecoza	Econazole Nitrate Foam 1%	1 %	1	Bottle	30	DAYS			
Ergomar	Ergotamine Tartrate SL Tab 2 MG	2 MG	20	Tablets	28	DAYS			
Ertaczo	Sertaconazole Nitrate Cream 2%	2 %	60	Grams	30	DAYS			
Exelderm ; Sulconazole nitrate	Sulconazole Nitrate Cream 1%	1 %	60	Grams	30	DAYS			
Exelderm ; Sulconazole nitrate	Sulconazole Nitrate Solution 1%	1 %	1	Bottle	30	DAYS			
Fenoglide	Fenofibrate Tab 120 MG	120 MG	30	Tablets	30	DAYS			
Fenoprofen calcium	Fenoprofen Calcium Cap 200 MG	200 MG	180	Capsules	30	DAYS			
Fenoprofen calcium ; Nalfon	Fenoprofen Calcium Tab 600 MG	600 MG	150	Tablets	30	DAYS			
Fenopron	fenoprofen calcium cap	300 MG	150	Capsules	30	DAYS			
Halcinonide ; Halog	Halcinonide Soln 0.1%	0.1 %	120	mLs	30	DAYS			
Inderal xl ; Innopran xl	Propranolol HCl Sustained-Release Beads Cap ER 24HR 120 MG	120 MG	30	Capsules	30	DAYS			
Inderal xl ; Innopran xl	Propranolol HCl Sustained-Release Beads Cap ER 24HR 80 MG	80 MG	30	Capsules	30	DAYS			
Kenalog ; Triamcinolone acetonide	Triamcinolone Acetonide Aerosol Soln 0.147 MG/GM	0.147 MG/GM	189	Grams	90	DAYS			
Ketoprofen	Ketoprofen Cap 50 MG	50 MG	180	Capsules	30	DAYS			
Ketoprofen ; Kiprofen	Ketoprofen Cap 25 MG	25 MG	360	Capsules	30	DAYS			
Ketoprofen er	Ketoprofen Cap ER 24HR 200 MG	200 MG	30	Capsules	30	DAYS			
Kitabis pak ; Tobi ; Tobramycin	Tobramycin Nebu Soln 300 MG/5ML	300 MG/5ML	280	mLs	56	DAYS	Any tobramycin product and Cayston cannot be filled within 28 days of each other. 224 mL = 56 ampules		
Konvomep	omeprazole-sodium bicarbonate for oral susp	2-84 MG/ML	600	mLs	30	DAYS			
Lexette	Halobetasol Propionate Foam 0.05%	0.05 %	180	Grams	90	DAYS	QL is cumulative across agents		

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	QL Amount	Dose Form	Day Supply	Duration	Addtl QL Info	Allowed Exceptions	Targeted NDCs When Exclusions Exist
Librax	Chlordiazepoxide HCl-Clidinium Bromide Cap 5-2.5 MG	5-2.5 MG	240	Capsules	30	DAYS			
Luliconazole ; Luzu	Luliconazole Cream 1%	1 %	60	Grams	30	DAYS			
Methocarbamol	Methocarbamol Tab	1000 MG	120	Tablets	30	DAYS			
Naftifine hydrochloride	Naftifine HCl Cream 1%	1 %	60	Grams	30	DAYS			
Naftin	Naftifine HCl Gel 1%	1 %	60	Grams	30	DAYS			
Naftin	Naftifine HCl Gel 2%	2 %	60	Grams	30	DAYS			
Nalfon	Fenoprofen Calcium Cap 400 MG	400 MG	120	Capsules	30	DAYS			
Naprelan	Naproxen Sodium Tab ER 24HR 375 MG (Base Equiv)	375 MG	60	Tablets	30	DAYS			
Naprelan	Naproxen Sodium Tab ER 24HR 500 MG (Base Equiv)	500 MG	60	Tablets	30	DAYS			
Naprelan	Naproxen Sodium Tab ER 24HR 750 MG (Base Equiv)	750 MG	60	Tablets	30	DAYS			
Noritate	Metronidazole Cream 1%	1 %	60	Grams	30	DAYS			
Oxistat	Oxiconazole Nitrate Cream 1%	1 %	120	Grams	30	DAYS			
Oxistat	Oxiconazole Nitrate Lotion 1%	1 %	120	mLs	30	DAYS			
Phospholine iodide	Echothiophate Iodide Ophth For Soln 0.125%	0.125 %	5	mLs	30	DAYS			
Rhofade	Oxymetazoline HCl Cream 1%	1 %	30	Grams	30	DAYS			
Sitavig	Acyclovir Buccal Tab 50 MG	50 MG	2	Tablets	180	DAYS			
Sovuna	hydroxychloroquine sulfate tab	200 MG	90	Tablets	30	DAYS			709540 80420
Sovuna	hydroxychloroquine sulfate tab	300 MG	60	Tablets	30	DAYS			709540 80510
Tobi podhaler	Tobramycin Inhal Cap 28 MG	28 MG	224	Capsules	56	DAYS			
Treximet	Sumatriptan-Naproxen Sodium Tab 85-500 MG	85-500 MG	18	Tablets	30	DAYS			
Xerese	Acyclovir-Hydrocortisone Cream 5-1%	5-1 %	5	Grams	30	DAYS			
Zegerid	Omeprazole-Sodium Bicarbonate Cap 20-1100 MG	20-1100 MG	60	Capsules	30	DAYS			
Zegerid	Omeprazole-Sodium Bicarbonate Cap 40-1100 MG	40-1100 MG	60	Capsules	30	DAYS			
Zegerid	Omeprazole-Sodium Bicarbonate Powd Pack for Susp 20-1680 MG	20-1680 MG	60	Packets	30	DAYS			
Zegerid	Omeprazole-Sodium Bicarbonate Powd Pack for Susp 40-1680 MG	40-1680 MG	60	Packets	30	DAYS			

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	QL Amount	Dose Form	Day Supply	Duration	Addtl QL Info	Allowed Exceptions	Targeted NDCs When Exclusions Exist
Zembrace symtouch	Sumatriptan Succinate Solution Auto-injector 3 MG/0.5ML	3 MG/0.5 ML	24	Pens	30	DAYS			
Zipor	Diclofenac Potassium Cap 25 MG	25 MG	120	Capsules	30	DAYS			
Zyflo	Zileuton Tab 600 MG	600 MG	120	Tablets	30	DAYS			

ADDITIONAL QUANTITY LIMIT INFORMATION

Wildcard	Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Additional QL Information	Targeted NDCs When Exclusions Exist	Effective Date	Term Date
07000070002530	Bethkis	Tobramycin Nebu Soln 300 MG/4ML	300 MG/4ML	Any tobramycin product and Cayston cannot be filled within 28 days of each other. 224 mL = 56 ampules			
07000070002520	Kitabis pak ; Tobi ; Tobramycin	Tobramycin Nebu Soln 300 MG/5ML	300 MG/5ML	Any tobramycin product and Cayston cannot be filled within 28 days of each other. 224 mL = 56 ampules			
90550073103920	Lexette	Halobetasol Propionate Foam 0.05%	0.05 %	QL is cumulative across agents			

CLIENT SUMMARY – PRIOR AUTHORIZATION

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Client Formulary
	Butalbital-Acetaminophen Tab 50-300 MG	50-300 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
	Chlorzoxazone Tab 375 MG	375 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Client Formulary
	Chlorzoxazone Tab 750 MG	750 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
	Cyclobenzaprine HCl Tab 7.5 MG	7.5 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
	Diclofenac Potassium Tab	25 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
	Diflorasone Diacetate Oint 0.05%	0.05 %	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
	Ketoconazole Foam 2%	2 %	Balanced ; Balanced Biosimilar ; Basic ; Basic

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Client Formulary
			Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
	Mefenamic Acid Cap 250 MG	250 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
	meloxicam cap	10 MG ; 5 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
	Mupirocin Calcium Cream 2%	2 %	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
	Naftifine HCl Cream 2%	2 %	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Client Formulary
			Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
	Prednisolone Sod Phosphate Oral Soln 10 MG/5ML (Base Equiv)	10 MG/5ML	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
	Prednisolone Tab 5 MG	5 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
	Zileuton Tab ER 12HR 600 MG	600 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Absorica		10 MG ; 20 MG ; 25 MG ; 30 MG ; 35 MG ; 40 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ;

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Client Formulary
			HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Absorica Id		16 MG ; 24 MG ; 32 MG ; 8 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Adapalene	Adapalene Pads 0.1%	0.1 %	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Airduo respiclick 113/14	fluticasone-salmeterol aer powder ba	113-14 MCG/ACT	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Airduo respiclick 232/14	fluticasone-salmeterol aer powder ba	232-14 MCG/ACT	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Client Formulary
			Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Airduo respiclick 55/14	fluticasone-salmeterol aer powder ba	55-14 MCG/ACT	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Ala-scalp ; Hydrocortisone	Hydrocortisone Lotion 2%	2 %	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Alphagan p	Brimonidine Tartrate Ophth Soln 0.15%	0.15 %	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Amrix	cyclobenzaprine hcl cap er	15 MG ; 30 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Client Formulary
			Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Aplenzin	bupropion hbr tab er	174 MG ; 348 MG ; 522 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Ativan		0.5 MG ; 1 MG ; 2 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Azelex	Azelaic Acid Cream 20%	20 %	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Bethkis		300 MG/4ML	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Client Formulary
			Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Cabtreo	adapalene-benzoyl peroxide-clindamycin gel	0.15-3.1-1.2 %	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Cafergot ; Ergotamine tartrate/caffe	Ergotamine w/ Caffeine Tab 1-100 MG	1-100 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Calcipotriene ; Sorilux	Calcipotriene Foam 0.005%	0.005 %	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Cambia	Diclofenac Potassium Packet 50 MG	50 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ;

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Client Formulary
			Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Carbinoxamine maleate	carbinoxamine maleate tab	6 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Chlorzoxazone	Chlorzoxazone Tab 250 MG	250 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Coxanto ; Oxaprozin	oxaprozin cap	300 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Cuprimine	penicillamine cap	250 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Client Formulary
Denavir	Penciclovir Cream 1%	1 %	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Diflorasone diacetate	Diflorasone Diacetate Cream 0.05%	0.05 %	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Doral ; Quazepam	Quazepam Tab 15 MG	15 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Ecoza	Econazole Nitrate Foam 1%	1 %	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Epinephrine	epinephrine solution auto-injector	0.15 MG/0.15ML	Balanced ; Balanced Biosimilar ; Basic ; Basic

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Client Formulary
			Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Epinephrine	epinephrine solution auto-injector	0.3 MG/0.3ML	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Ergomar	Ergotamine Tartrate SL Tab 2 MG	2 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Ertaczo	Sertaconazole Nitrate Cream 2%	2 %	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Exelderm ; Sulconazole nitrate	Sulconazole Nitrate Cream 1%	1 %	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Client Formulary
			Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Exelderm ; Sulconazole nitrate	Sulconazole Nitrate Solution 1%	1 %	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Fenoglide	Fenofibrate Tab 120 MG	120 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Fenoprofen calcium ; Fenopron ; Nalfon	fenoprofen calcium cap	200 MG ; 300 MG ; 400 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Fenoprofen calcium ; Nalfon	Fenoprofen Calcium Tab 600 MG	600 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ;

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Client Formulary
			HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Flurandrenolide	Flurandrenolide Lotion 0.05%	0.05 %	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Flurazepam hydrochloride		15 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Flurazepam hydrochloride		30 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Halcinonide ; Halog	Halcinonide Soln 0.1%	0.1 %	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Client Formulary
			Performance Select ; Performance Select Biosimilar ; Whole Foods
Inderal xl ; Innopran xl	Propranolol HCl Sustained-Release Beads Cap ER 24HR 120 MG	120 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Inderal xl ; Innopran xl	Propranolol HCl Sustained-Release Beads Cap ER 24HR 80 MG	80 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Kenalog ; Triamcinolone acetonide	triamcinolone acetonide aerosol soln	0.147 MG/GM	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Ketoprofen	Ketoprofen Cap 50 MG	50 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Client Formulary
			Performance Select Biosimilar ; Whole Foods
Ketoprofen ; Kiprofen	Ketoprofen Cap 25 MG	25 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Ketoprofen er	Ketoprofen Cap ER 24HR 200 MG	200 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Kitabis pak ; Tobi ; Tobramycin		300 MG/5ML	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Konvomep ; Zegerid	omeprazole-sodium bicarbonate cap ; omeprazole-sodium bicarbonate for oral susp ; omeprazole-sodium bicarbonate powd pack for susp	2-84 MG/ML ; 20-1100 MG ; 20-1680 MG ; 40-1100 MG ; 40-1680 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Client Formulary
Lexette	Halobetasol Propionate Foam 0.05%	0.05 %	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Librax		5-2.5 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Luliconazole ; Luzu	Luliconazole Cream 1%	1 %	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Methocarbamol	Methocarbamol Tab	1000 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Naftifine hydrochloride	Naftifine HCl Cream 1%	1 %	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2026 ;

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Client Formulary
			HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Naftin	Naftifine HCl Gel 1%	1 %	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Naftin	Naftifine HCl Gel 2%	2 %	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Nalocet ; Oxycodone/acetaminophen	Oxycodone w/ Acetaminophen Tab 2.5-300 MG	2.5-300 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Naprelan	Naproxen Sodium Tab ER 24HR 375 MG (Base Equiv)	375 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Client Formulary
			Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Naprelan	Naproxen Sodium Tab ER 24HR 500 MG (Base Equiv)	500 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Naprelan	Naproxen Sodium Tab ER 24HR 750 MG (Base Equiv)	750 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Neffy	epinephrine nasal spray	1 MG/0.1ML	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Neffy	epinephrine nasal spray	2 MG/0.1ML	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Client Formulary
			Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Noritate	Metronidazole Cream 1%	1 %	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Oxistat	Oxiconazole Nitrate Cream 1%	1 %	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Oxistat	Oxiconazole Nitrate Lotion 1%	1 %	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Oxycodone and acetaminoph ; Prolate	Oxycodone w/ Acetaminophen Tab 7.5-300 MG	7.5-300 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Client Formulary
			Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Oxycodone/acetaminophen ; Prolate	Oxycodone w/ Acetaminophen Tab 10-300 MG	10-300 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Oxycodone/acetaminophen ; Prolate	Oxycodone w/ Acetaminophen Tab 5-300 MG	5-300 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Phospholine iodide	Echothiophate Iodide Ophth For Soln 0.125%	0.125 %	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Reltone ; Ursodiol	Ursodiol Cap	200 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ;

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Client Formulary
			Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Reltone ; Ursodiol	Ursodiol Cap	400 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Rhofade	oxymetazoline hcl cream	1 %	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Sitavig	Acyclovir Buccal Tab 50 MG	50 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Sovuna	hydroxychloroquine sulfate tab	200 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Client Formulary
Sovuna	hydroxychloroquine sulfate tab	300 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Tobi podhaler	tobramycin inhal cap	28 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Treximet	Sumatriptan-Naproxen Sodium Tab 85-500 MG	85-500 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Wellbutrin xl		150 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Wellbutrin xl		300 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ;

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Client Formulary
			HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Xerese	Acyclovir-Hydrocortisone Cream 5-1%	5-1 %	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Zembrace symtouch	Sumatriptan Succinate Solution Auto-injector 3 MG/0.5ML	3 MG/0.5ML	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Zipsor	Diclofenac Potassium Cap 25 MG	25 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Zovirax	Acyclovir Cream 5%	5 %	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Client Formulary
			Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Zyflo	zileuton tab	600 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods

CLIENT SUMMARY – QUANTITY LIMITS

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Client Formulary
	Butalbital-Acetaminophen Tab 50-300 MG	50-300 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
	Chlorzoxazone Tab 375 MG	375 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
	Chlorzoxazone Tab 750 MG	750 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Client Formulary
			Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
	Cyclobenzaprine HCl Tab 7.5 MG	7.5 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
	Diclofenac Potassium Tab	25 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
	Diflorasone Diacetate Oint 0.05%	0.05 %	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
	Ketoconazole Foam 2%	2 %	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ;

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Client Formulary
			HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
	Mefenamic Acid Cap 250 MG	250 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
	Meloxicam Cap 10 MG	10 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
	Meloxicam Cap 5 MG	5 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
	Mupirocin Calcium Cream 2%	2 %	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Client Formulary
			Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
	Naftifine HCl Cream 2%	2 %	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
	Prednisolone Sod Phosphate Oral Soln 10 MG/5ML (Base Equiv)	10 MG/5ML	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
	Zileuton Tab ER 12HR 600 MG	600 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Absorica	Isotretinoin Cap 10 MG	10 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Client Formulary
			Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Absorica	Isotretinoin Cap 20 MG	20 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Absorica	Isotretinoin Cap 25 MG	25 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Absorica	Isotretinoin Cap 30 MG	30 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Absorica	Isotretinoin Cap 35 MG	35 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Client Formulary
			Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Absorica	Isotretinoin Cap 40 MG	40 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Absorica Id	Isotretinoin Micronized Cap 16 MG	16 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Absorica Id	Isotretinoin Micronized Cap 24 MG	24 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Absorica Id	Isotretinoin Micronized Cap 32 MG	32 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ;

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Client Formulary
			Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Absorica Id	Isotretinoin Micronized Cap 8 MG	8 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Adapalene	Adapalene Pads 0.1%	0.1 %	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Airduo respiclick 113/14 ; Fluticasone propionate/sa	Fluticasone-Salmeterol Aer Powder BA 113-14 MCG/ACT	113-14 MCG/ACT	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Airduo respiclick 232/14 ; Fluticasone propionate/sa	Fluticasone-Salmeterol Aer Powder BA 232-14 MCG/ACT	232-14 MCG/ACT	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ;

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Client Formulary
			Performance Select ; Performance Select Biosimilar ; Whole Foods
Airduo respiclick 55/14 ; Fluticasone propionate/sa	Fluticasone-Salmeterol Aer Powder BA 55-14 MCG/ACT	55-14 MCG/ACT	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Alphagan p	Brimonidine Tartrate Ophth Soln 0.15%	0.15 %	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Amrix	Cyclobenzaprine HCl Cap ER 24HR 15 MG	15 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Amrix	Cyclobenzaprine HCl Cap ER 24HR 30 MG	30 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Client Formulary
			Performance Select Biosimilar ; Whole Foods
Ativan	Lorazepam Tab 0.5 MG	0.5 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Ativan	Lorazepam Tab 1 MG	1 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Ativan	Lorazepam Tab 2 MG	2 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Azelex	Azelaic Acid Cream 20%	20 %	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Client Formulary
Bethkis	Tobramycin Nebu Soln 300 MG/4ML	300 MG/4ML	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Cafergot ; Ergotamine tartrate/caffe	Ergotamine w/ Caffeine Tab 1-100 MG	1-100 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Calcipotriene ; Sorilux	Calcipotriene Foam 0.005%	0.005 %	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Cambia	Diclofenac Potassium Packet 50 MG	50 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Carbinoxamine maleate	carbinoxamine maleate tab	6 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Client Formulary
			Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Chlorzoxazone	Chlorzoxazone Tab 250 MG	250 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Coxanto ; Oxaprozin	oxaprozin cap	300 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Cuprimine	Penicillamine Cap 250 MG	250 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Diflorasone diacetate	Diflorasone Diacetate Cream 0.05%	0.05 %	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Client Formulary
			Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Doral ; Quazepam	Quazepam Tab 15 MG	15 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Ecoza	Econazole Nitrate Foam 1%	1 %	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Ergomar	Ergotamine Tartrate SL Tab 2 MG	2 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Ertaczo	Sertaconazole Nitrate Cream 2%	2 %	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ;

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Client Formulary
			HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Exelderm ; Sulconazole nitrate	Sulconazole Nitrate Cream 1%	1 %	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Exelderm ; Sulconazole nitrate	Sulconazole Nitrate Solution 1%	1 %	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Fenoglide	Fenofibrate Tab 120 MG	120 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Fenoprofen calcium	Fenoprofen Calcium Cap 200 MG	200 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Client Formulary
			Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Fenoprofen calcium ; Nalfon	Fenoprofen Calcium Tab 600 MG	600 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Fenopron	fenoprofen calcium cap	300 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Halcinonide ; Halog	Halcinonide Soln 0.1%	0.1 %	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Inderal xl ; Innopran xl	Propranolol HCl Sustained-Release Beads Cap ER 24HR 120 MG	120 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Client Formulary
			Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Inderal xl ; Innopran xl	Propranolol HCl Sustained-Release Beads Cap ER 24HR 80 MG	80 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Kenalog ; Triamcinolone acetonide	Triamcinolone Acetonide Aerosol Soln 0.147 MG/GM	0.147 MG/GM	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Ketoprofen	Ketoprofen Cap 50 MG	50 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Ketoprofen ; Kiprofen	Ketoprofen Cap 25 MG	25 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Client Formulary
			Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Ketoprofen er	Ketoprofen Cap ER 24HR 200 MG	200 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Kitabis pak ; Tobi ; Tobramycin	Tobramycin Nebu Soln 300 MG/5ML	300 MG/5ML	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Konvomep	omeprazole-sodium bicarbonate for oral susp	2-84 MG/ML	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Lexette	Halobetasol Propionate Foam 0.05%	0.05 %	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ;

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Client Formulary
			Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Librax	Chlordiazepoxide HCl-Clidinium Bromide Cap 5-2.5 MG	5-2.5 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Luliconazole ; Luzu	Luliconazole Cream 1%	1 %	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Methocarbamol	Methocarbamol Tab	1000 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Naftifine hydrochloride	Naftifine HCl Cream 1%	1 %	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ;

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Client Formulary
			Performance Select ; Performance Select Biosimilar ; Whole Foods
Naftin	Naftifine HCl Gel 1%	1 %	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Naftin	Naftifine HCl Gel 2%	2 %	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Nalfon	Fenoprofen Calcium Cap 400 MG	400 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Naprelan	Naproxen Sodium Tab ER 24HR 375 MG (Base Equiv)	375 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Client Formulary
			Performance Select Biosimilar ; Whole Foods
Napreelan	Naproxen Sodium Tab ER 24HR 500 MG (Base Equiv)	500 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Napreelan	Naproxen Sodium Tab ER 24HR 750 MG (Base Equiv)	750 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Noritate	Metronidazole Cream 1%	1 %	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Oxistat	Oxiconazole Nitrate Cream 1%	1 %	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Client Formulary
Oxistat	Oxiconazole Nitrate Lotion 1%	1 %	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Phospholine iodide	Echothiophate Iodide Ophth For Soln 0.125%	0.125 %	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Rhofade	Oxymetazoline HCl Cream 1%	1 %	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Sitavig	Acyclovir Buccal Tab 50 MG	50 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Sovuna	hydroxychloroquine sulfate tab	300 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Client Formulary
			Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Sovuna	hydroxychloroquine sulfate tab	200 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Tobi podhaler	Tobramycin Inhal Cap 28 MG	28 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Treximet	Sumatriptan-Naproxen Sodium Tab 85-500 MG	85-500 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Xerese	Acyclovir-Hydrocortisone Cream 5-1%	5-1 %	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Client Formulary
			Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Zegerid	Omeprazole-Sodium Bicarbonate Cap 20-1100 MG	20-1100 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Zegerid	Omeprazole-Sodium Bicarbonate Cap 40-1100 MG	40-1100 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Zegerid	Omeprazole-Sodium Bicarbonate Powd Pack for Susp 20-1680 MG	20-1680 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Zegerid	Omeprazole-Sodium Bicarbonate Powd Pack for Susp 40-1680 MG	40-1680 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ;

Target Brand Agent Name(s)	Target Generic Agent Name(s)	Strength	Client Formulary
			HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Zembrace symtouch	Sumatriptan Succinate Solution Auto-injector 3 MG/0.5ML	3 MG/0.5ML	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Zipsor	Diclofenac Potassium Cap 25 MG	25 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods
Zyflo	Zileuton Tab 600 MG	600 MG	Balanced ; Balanced Biosimilar ; Basic ; Basic Annual ; Enhanced ; Enhanced Annual ; HIM Annual 2024 ; HIM Annual 2025 ; HIM Annual 2026 ; HIM Quarterly 2024 ; HIM Quarterly 2025 ; HIM Quarterly 2026 ; NM HIM Annual 2024 ; NM HIM Annual 2025 ; NM HIM Annual 2026 ; NM Performance ; Performance ; Performance Annual ; Performance Biosimilar ; Performance Select ; Performance Select Biosimilar ; Whole Foods

PRIOR AUTHORIZATION CLINICAL CRITERIA FOR APPROVAL

Module	Clinical Criteria for Approval
	<p>Initial</p> <p>Target Agents will be approved when ALL of the following are met:</p> <ol style="list-style-type: none"> 1. The patient has an FDA labeled or Compendia approved indication for the requested agent AND 2. The patient does NOT have any FDA labeled contraindications to the requested agent AND 3. ONE of the following: <ol style="list-style-type: none"> A. BOTH of the following: <ol style="list-style-type: none"> 1. ONE of the following: <ol style="list-style-type: none"> A. The prescriber has stated that the patient has been diagnosed with stage four advanced, metastatic cancer and the requested agent is being used to treat the cancer OR B. The prescriber has submitted documentation that the patient has been diagnosed with stage four advanced, metastatic cancer and the requested agent is being used to treat an associated condition related to stage four advanced metastatic cancer [chart notes are required] AND 2. The use of the requested agent is consistent with best practices for the treatment of stage four advanced, metastatic cancer, or an associated condition; supported by peer-reviewed, evidence-based literature; and approved by the United States Food and Drug Administration OR B. The patient is currently being treated with the requested agent and the patient is currently stable on the requested agent [chart notes are required] OR C. The patient has tried and had an inadequate response to optimized therapy of ONE more cost-effective, clinically appropriate, formulary alternative [chart notes are required] OR D. Optimized therapy of ONE more cost-effective, clinically appropriate, formulary alternative was discontinued due to lack of efficacy or effectiveness, diminished effect, or an adverse event [chart notes are required] OR E. The patient has an intolerance or hypersensitivity to ONE more cost-effective, clinically appropriate, formulary alternative that is not expected to occur with the requested agent [chart notes are required] OR F. The patient has an FDA labeled contraindication to ONE more cost-effective, clinically appropriate, formulary alternative that is not expected to occur with the requested agent [chart notes are required] OR G. Optimized therapy of ONE more cost-effective, clinically appropriate, formulary alternative is expected to be ineffective based on the known clinical characteristics of the patient and the known characteristics of the prescription drug; OR cause a significant barrier to the patient's adherence of care; OR worsen a comorbid condition; OR decrease the patient's ability to achieve or maintain reasonable functional ability in performing daily activities; OR cause an adverse reaction or cause physical or mental harm [chart notes are required] OR H. Optimized therapy of ONE more cost-effective, clinically appropriate, formulary alternative is not in the best interest of the patient based on medical necessity [chart notes are required] OR I. The patient has tried another prescription drug in the same pharmacologic class or with the same mechanism of action as optimized therapy of a more cost-effective, clinically appropriate, formulary alternative and that prescription drug was discontinued due to lack of efficacy or effectiveness, diminished effect, or an adverse event [chart notes are required] <p>Compendia Allowed: AHFS, or DrugDex 1, 2a, or 2b level of evidence</p> <p>Length of Approval: 12 months</p> <p>NOTE: if Quantity Limit applies, please refer to Quantity Limit Criteria</p>

Module	Clinical Criteria for Approval												
	<p>The requested agent will also be approved when the following are met:</p> <ol style="list-style-type: none"> 1. The member resides in Ohio AND 2. The plan is Fully Insured or HIM Shop (SG) AND BOTH of the following <ol style="list-style-type: none"> A. The patient does NOT have any FDA labeled contraindications to the requested agent AND B. ONE of the following: <ol style="list-style-type: none"> 1. The patient has another FDA labeled indication for the requested agent and route of administration OR 2. The patient has another indication that is supported in compendia for the requested agent and route of administration OR 3. The prescriber has submitted TWO articles from major peer-reviewed professional medical journals [e.g., Journal of American Medical Association (JAMA), New England Journal of Medicine (NEJM), Lancet] supporting the proposed use(s) as generally safe and effective. Accepted study designs may include, but are not limited to, randomized, double blind, placebo controlled clinical trials. NOTE: Case studies are not acceptable [journal articles required] <p>Non-oncology compendia allowed: DrugDex level 1, 2A or 2B, AHFS-DI (narrative text must be supportive)</p> <p>Oncology compendia allowed: NCCN 1 or 2A, AHFS-DI (narrative text must be supportive), DrugDex level 1, 2A, or 2B, or Clinical Pharmacology (narrative text must be supportive), Lexi-Drugs evidence level A, peer-reviewed medical literature</p> <p>Length of Approval: 12 months</p> <p>NOTE: If Quantity Limit applies, please refer to Quantity Limit Criteria</p> <p>Renewal</p> <p>Target Agents will be approved when the following is met:</p> <ol style="list-style-type: none"> 1. The patient was previously approved for the requested agent through the Prime Therapeutics Prior Authorization process in the previous 18 months <p>Length of Approval: 12 months</p> <p>NOTE: if Quantity Limit applies, please refer to Quantity Limit Criteria</p> <table border="1" data-bbox="233 1648 1421 1953"> <thead> <tr> <th data-bbox="233 1648 740 1707">Target Agents</th><th data-bbox="740 1648 1421 1707">More cost-effective, clinically appropriate, formulary alternatives</th></tr> </thead> <tbody> <tr> <td data-bbox="233 1707 740 1766">Absorica/Absorica LD (isotretinoin)</td><td data-bbox="740 1707 1421 1766">Generic isotretinoin (Claravis, Amnesteem, Zenatane, Myorisan, Accutane)</td></tr> <tr> <td data-bbox="233 1766 740 1799">Adapalene pads</td><td data-bbox="740 1766 1421 1799">Generic adapalene, tretinoin, tazarotene cream</td></tr> <tr> <td data-bbox="233 1799 740 1858">AirDuo (fluticasone/salmeterol)</td><td data-bbox="740 1799 1421 1858">fluticasone-salmeterol aer powder ba 100-50 mcg/act, 250-50 mcg/act, 500-50 mcg/act (generic Advair Disku)</td></tr> <tr> <td data-bbox="233 1858 740 1917">Ala-Scalp (hydrocortisone)</td><td data-bbox="740 1858 1421 1917">Generic hydrocortisone cream 2.5%, hydrocortisone lotion 2.5%</td></tr> <tr> <td data-bbox="233 1917 740 1953">Alphagan-P (brimonidine 0.15%)</td><td data-bbox="740 1917 1421 1953">Generic brimonidine 0.2% ophthalmic solution</td></tr> </tbody> </table>	Target Agents	More cost-effective, clinically appropriate, formulary alternatives	Absorica/Absorica LD (isotretinoin)	Generic isotretinoin (Claravis, Amnesteem, Zenatane, Myorisan, Accutane)	Adapalene pads	Generic adapalene, tretinoin, tazarotene cream	AirDuo (fluticasone/salmeterol)	fluticasone-salmeterol aer powder ba 100-50 mcg/act, 250-50 mcg/act, 500-50 mcg/act (generic Advair Disku)	Ala-Scalp (hydrocortisone)	Generic hydrocortisone cream 2.5%, hydrocortisone lotion 2.5%	Alphagan-P (brimonidine 0.15%)	Generic brimonidine 0.2% ophthalmic solution
Target Agents	More cost-effective, clinically appropriate, formulary alternatives												
Absorica/Absorica LD (isotretinoin)	Generic isotretinoin (Claravis, Amnesteem, Zenatane, Myorisan, Accutane)												
Adapalene pads	Generic adapalene, tretinoin, tazarotene cream												
AirDuo (fluticasone/salmeterol)	fluticasone-salmeterol aer powder ba 100-50 mcg/act, 250-50 mcg/act, 500-50 mcg/act (generic Advair Disku)												
Ala-Scalp (hydrocortisone)	Generic hydrocortisone cream 2.5%, hydrocortisone lotion 2.5%												
Alphagan-P (brimonidine 0.15%)	Generic brimonidine 0.2% ophthalmic solution												

Module	Clinical Criteria for Approval	
	Amrix (cyclobenzaprine SR)	Generic cyclobenzaprine 5mg, 10mg tablets; Generic tizanidine 2mg, 4mg tablets; chlorzoxazone tab 500 mg
	Lorzone (chlorzoxazone)	
	Fexmid (cyclobenzaprine)	
	Tanlor (methocarbamol 1000 mg)	
	Aplenzin (bupropion hydrobromide)	Generic bupropion extended-release
	Wellbutrin XL (bupropion extended-release)	
	Ativan (lorazepam)	Generic lorazepam
	Azelex (azelaic acid)	Generic clindamycin, erythromycin, metronidazole, benzoyl peroxide, sulfacetamide; generic combinations
	Bethkis (tobramycin)	Generic tobramycin 300 mg/5 mL inhalation solution, generic tobramycin 300 mg/ 4 mL inhalation solution
	TOBI/Kitabis (tobramycin)	
	TOBI Podhaler (tobramycin)	
	Bupap (butalbital/acetaminophen)	Butalbital/acetaminophen (MSC=Y) 50/325 GPI 64991002120310
	Cabtreo (adapalene/benzoyl peroxide/clindamycin 0.15/3.1/1.2%) gel	generic topical retinoid or generic topical antibiotic
	Cafergot (ergotamine/cafeine)	Generic triptans (e.g. sumatriptan, eletriptan, naratriptan, rizatriptan, zolmitriptan)
	Ergomar (ergotamine)	
	Cambia (diclofenac potassium)	Generic prescription oral NSAID (that is not a target)
	Diclofenac potassium 25 mg tabs	
	Ketoprofen 25 mg capsule	
	Ketoprofen 50 mg capsule	
	Ketoprofen ER 200 mg capsule ER	
	Lofena (diclofenac potassium)	
	Mefenamic acid	
	Nalfon/Fenoprofen	
	Zipsor (diclofenac potassium)	
	Carbinoxamine tab 6mg	carbinoxamine 4mg immediate release tablets, solution
	Cordran, Nolix (flurandrenolide lotion)	Generic betamethasone dip lotion 0.1%, triamcinolone acetonide lotion 0.1%
	Coxanto/oxaprozin 300mg	oxaprozin 600mg
	Cuprimine (penicillamine caps)	Penicillamine tablet 250 mg
	Denavir (penciclovir cream)	Acyclovir Tab 400 mg, Valacyclovir 2g, Famciclovir 1.5g, Acyclovir ointment, Abreva OTC
	Diflorasone cream	Generic betamethasone (Diprolene AF 0.05% cream), desoximetasone (Topicort 0.25% cream/ointment), any other same potency generic topical corticosteroid
	Diflorasone ointment	

Module	Clinical Criteria for Approval	
	Doral (quazepam)	generic temazepam, generic flurazepam, generic zolpidem
	Ecoza (econazole nitrate foam)	Ciclopirox olamine cream 0.77%, Econazole nitrate cream 1%, Ketoconazole cream 2%
	Exelderm (sulconazole cream/soln)	
	Luzu (luliconazole)	
	Naftin Gel (naftifine hydrochloride), Naftifine Cream	
	Oxistat (oxiconazole)	
	Epinephrine (Adrenaclick Authorized Generic) 0.15 mg auto-injector	Generic Epipen 0.15 mg NDC 49502-0101-** or Auvi-Q
	Epinephrine (Adrenaclick Authorized Generic) 0.3 mg auto-injector	Generic Epipen 0.3 mg NDC 49502-0102-** or Auvi-Q
	Ertaczo (sertaconazole nitrate)	Ciclopirox gel 0.77%, Ketoconazole cream 2%
	Extina, Ketodan (ketoconazole foam)	Ketoconazole shampoo 2%, ketoconazole 2% cream
	Fenoglide (fenofibrate 120mg)	Generic fenofibrate 48 mg, 54 mg, 145 mg, 160 mg
	Flurazepam 15mg and 30mg capsules	Generic temazepam, triazolam, estazolam
	Halog Halcinonide 0.1% soln	Generic fluocinonide soln 0.05%
	Inderal XL/ Innopran XL (propranolol extended-release) 80 mg capsule	Generic propranolol ER capsules (GPI 33100040107030)
	Inderal XL/ Innopran XL (propranolol extended-release) 120 mg capsule	Generic propranolol ER capsules (GPI 33100040107035)
	Kenalog (triamcinolone spray)	Generic triamcinolone 0.1% cream, Generic triamcinolone 0.1% lotion
	Lexette (halobetasol propionate foam)	Generic clobetasol propionate 0.05% cream, ointment, solution
	Librax (chlordiazepoxide/clidinium)	IBS: dicyclomine, Viberzi Peptic Ulcer Disease: generic prescription or OTC proton pump inhibitor
	meloxicam capsules	generic meloxicam tablets
	Mupirocin 2% cream	Generic mupirocin ointment
	Nalcet (oxycodone w/acetaminophen 2.5-300 mg) tablet	Generic oxycodone w/acetaminophen 2.5-325 mg tablet
	Naprelan (naproxen sodium, ER)	Generic prescription or OTC immediate release naproxen tablets
	Noritate (metronidazole cream)	Metronidazole (gel, cream), sulfacetamide
	Prednisolone sodium phosphate oral solution 10mg/5mL	Other strengths of prednisolone solution
	Prolate (oxycodone w/ acetaminophen 5-300 mg) tablet	Generic oxycodone w/ acetaminophen 5-325 mg tablet
	Prolate (oxycodone w/ acetaminophen 7.5-300 mg) tablet	Generic oxycodone w/ acetaminophen 7.5-325 mg tablet
	Prolate (oxycodone w/ acetaminophen 10-300 mg) tablet	Generic oxycodone w/ acetaminophen 10-325 mg tablet
	Millipred/Prednisolone tablet	Prednisone 5 mg tab, prednisone solution, prednisolone syrup
	Neffy (epinephrine 2mg/0.1mL) nasal spray	Generic Epipen 0.15 mg NDC 49502-0101-** or Generic Epipen 0.3 mg NDC 49502-0102-** or Auvi-Q
	Phospholine iodide ophthalmic solution	Latanoprost, Pilocarpine
	Reltone (ursodiol)	Generic ursodiol 300 mg capsule
	Rhofade (oxymetazoline hydrochloride)	Azelaic acid Gel 15%, Topical metronidazole (cream, gel, lotion)

Module	Clinical Criteria for Approval	
	Sitavig (acyclovir)	Generic oral acyclovir, generic oral valacyclovir
	Sorilux (calcipotriene)	Calcipotriene 0.005% solution, cream
	Sovuna 200mg	Generic hydroxychloroquine tab 200 mg
	Sovuna 300mg	Generic hydroxychloroquine tab 300 mg
	Treximet (sumatriptan/naproxen)	Separate agents taken together: a generic triptan with a generic NSAID (that is not a target)
	Xerese (acyclovir/hydrocortisone)	Generic oral acyclovir, famciclovir, valacyclovir tablets/capsules
	Zegerid/Konvomep (omeprazole/sodium bicarbonate)	Generic omeprazole, pantoprazole
	Zembrace (sumatriptan auto-injector)	Generic sumatriptan (auto-injectors, syringes, vials)
	Zovirax (acyclovir cream)	Acyclovir 400 mg tablets, valacyclovir tablets, famciclovir tablets, acyclovir ointment, Abreva OTC
	Zyflo (zileuton), zileuton ER	Generic montelukast

QUANTITY LIMIT CLINICAL CRITERIA FOR APPROVAL

Module	Clinical Criteria for Approval
	<p>Quantity Limit for the Target Agent(s) will be approved when ONE of the following is met:</p> <ol style="list-style-type: none"> The requested quantity (dose) does NOT exceed the program quantity limit OR ALL of the following: <ol style="list-style-type: none"> The requested quantity (dose) is greater than the program quantity limit AND The requested quantity (dose) does not exceed the maximum FDA labeled dose AND The requested quantity (dose) cannot be achieved with a lower quantity of a higher strength that does not exceed the program quantity limit AND The dosage increase requested is appropriate based on recommended dosage titrations in FDA labeling or Compendia (i.e. dosage increase is not excessive, patient has been on current dose a sufficient length of time to determine efficacy/adverse effects) OR ALL of the following: <ol style="list-style-type: none"> The requested quantity (dose) is greater than the program quantity limit AND The requested quantity (dose) is greater than the maximum FDA labeled dose for the requested indication AND The prescriber has submitted documentation in support of therapy with a higher dose for the requested indication <p>Compendia Allowed: AHFS, or DrugDex 1, 2a, or 2b level of evidence</p> <p>Length of Approval: 12 months</p>